Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology

Volumn 73, Issue 1, 2015, Pages 37-49

  Papp, Kim ^a   Reich, Kristian ^b   Leonardi, Craig L ^c   Kircik, Leon ^d,e   Chimenti, Sergio ^f   Langley, Richard G B ^g   Hu, ChiaChi ^h   Stevens, Randall M ^h   Day, Robert M ^h   Gordon, Kenneth B ⁱ   Korman, Neil J ^j   Griffiths, Christopher E M ^k  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b DERMATOLOGIKUM HAMBURG   (Germany)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e Physicians Skin Care PLLC   (United States)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g DALHOUSIE UNIVERSITY   (Canada)

^h CELGENE CORPORATION   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

apremilast; clinical trial; ESTEEM; phosphodiesterase 4 inhibitor; psoriasis; treatment

Indexed keywords

APREMILAST; PLACEBO; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ASTHENIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NEPHROLITHIASIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; SKIN CARCINOMA; TENSION HEADACHE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 84937880965     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.03.049     Document Type: Article

References (19)

1. M.D. Houslay, P. Schafer, and K.Y. Zhang Keynote review: phosphodiesterase-4 as a therapeutic target Drug Discov Today 10 2005 1503 1519
2. P. Schafer Apremilast mechanism of action and application to psoriasis and psoriatic arthritis Biochem Pharmacol 83 2012 1583 1590
3. A.B. Gottlieb, B. Strober, J.G. Krueger, and et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast Curr Med Res Opin 24 2008 1529 1538
4. A.B. Gottlieb, R.T. Matheson, A. Menter, and et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study J Drugs Dermatol 12 2013 888 897
5. J.A. Lambert, S.V. Raju, L.P. Tang, and et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis Am J Respir Cell Mol Biol 50 2014 549 558
6. R. Zhang, E. Maratos-Flier, and J.S. Flier Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B Endocrinology 150 2009 3076 3082
7. Otezla [package insert] 2014 Celgene Corporation Summit, NJ Available from: URL http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66 Accessed March 18, 2015
8. Otezla [summary of product characteristics] 2015 Celgene Europe Ltd Uxbridge, United Kingdom Available from: URL http://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx-130395-en.pdf Accessed March 18, 2015
9. Soriatane [package insert] 2014 Stiefel Laboratories Inc Research Triangle Park, NC Available from: URL http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cec7851f-c7af-4e9e-a5e4-a585c70510d2 Accessed March 18, 2015
10. Neoral [package insert] 2013 Novartis Pharmaceuticals Corporation East Hanover, NJ Available from: URL http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3 Accessed March 18, 2015
11. Methotrexate [package insert] 2009 DAVA Pharmaceuticals Inc Fort Lee, NJ Available from: URL http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c4a4784-b063-4c8f-b915-aeb18cb149be Accessed March 18, 2015
12. Oxsoralen-Ultra [package insert] 2015 Valeant Pharmaceuticals North America LLC Bridgewater, NJ Available from: URL http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae951dc4-9031-43bf-943c-cb2366951f23 Accessed March 18, 2015
13. M.G. Lebwohl, H. Bachelez, J. Barker, and et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey J Am Acad Dermatol 70 2014 871 881.e30
14. A.W. Armstrong, A.D. Robertson, J. Wu, C. Schupp, and M.G. Lebwohl Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011 JAMA Dermatol 149 2013 1180 1185
15. A. Menter, A. Gottlieb, S.R. Feldman, and et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
16. K. Kragballe Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails Curr Probl Dermatol 38 2009 160 171
17. A. Kavanaugh, P.J. Mease, J.J. Gomez-Reino, and et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Ann Rheum Dis 73 2014 1020 1026
18. R.M. Poole, and A.D. Ballantyne Apremilast: first global approval Drugs 74 2014 825 837
19. A. Kavanaugh, P.J. Mease, J.J. Gomez-Reino, and et al. Long-term (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis J Rheumatol 42 2015 479 488